PA007543.r2a: In Vivo Grade Recombinant Anti-mouse LPAM-1 (Intergrin α4β7) Monoclonal Antibody (Clone: DATK32), Rat IgG2a Kappa
Recombinant Rat IgG2a Monoclonal Antibody.
Clone: DATK32.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse LPAM-1 (Intergrin α4β7) monoclonal antibody (clone: DATK32) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: DATK32) specifically binds to mouse LPAM-1 (Intergrin α4β7) .
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse LPAM-1 (Intergrin α4β7) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-mouse LPAM-1 (Intergrin α4β7) monoclonal antibody of clone DATK32 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-mouse LPAM-1 (Intergrin alpha 4 beta 7) antibody (Clone: DATK32):
Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics
Wahl, R. L., et al. J Nucl Med. 2016 Apr;57(4):612-7. doi: 10.2967/jnumed.115.167387. PMID: 26841223
We previously reported increased intestinal uptake of a Cu-labeled anti-?7 integrin antibody (clone FIB504.64) in colitic mice. Here, we evaluated an anti-?4?7 integrin antibody (clone DATK32), and the F(ab')2 and Fab fragments of the anti-?7 antibody, which should have faster blood clearance than the intact antibody, as imaging probes for the detection of colitis in a mouse model. The ratio of uptake of DATK32 between the colitis and control groups in the large intestine (1.38) was lower than for the FIB504.64 fragments (3.15 for F(ab')2, 1.84 for Fab) or intact FIB504.64 (1.78). The lower intestinal uptake ratio of the Cu-labeled anti-?4?7 antibody (DATK32) compared with the anti-?7 immunoproteins suggests that targeting all ?7-expressing lymphocytes, not just those expressing ?4?7, is a more promising route to the development of an inflammatory bowel disease imaging agent. Blood concentrations at 24 hours postinjection were 23.3 ± 3.0% ID/g for Cu-labeled DATK32, 12.9 ± 2.1% ID/g for FIB504.64, 4.1 ± 0.4% ID/g for FIB504.64-F(ab')2, and 0.62 ± 0.2% ID/g for FIB504.64-Fab (P < 0.0001, analysis of variance). Focal uptake of the anti-?7 fragments was observed in the gut as early as 1 hour postinjection, and they cleared more rapidly from normal tissues than the whole antibody.
Tags: anti-mouse LPAM-1 (Intergrin ?4?7) DATK32; anti-mouse LPAM-1 (Intergrin ?4?7) DATK32 in vivo
Distribution of alpha 4 beta 7 and alpha E beta 7 integrins on thymocytes, intestinal epithelial lymphocytes and peripheral lymphocytes
Kilshaw, P. J., & Murant, S. J. Eur J Immunol. 1996 May;26(5):1067-74. doi: 10.1002/eji.1830260513. PMID: 8625986
Beta 7 is expressed on subsets of thymocytes, while T and B lymphocytes show heterogeneous expression of beta 7. Here, we examine the phenotype of the thymocyte and lymphocyte subsets which express alpha 4 beta 7 and alpha E beta 7 using mAb against alpha E, beta 7 and mAb DATK32 which recognizes a combinatorial epitope on alpha 4 beta 7. ?4?7+ thymocytes have a mature phenotype: TcR+, CD11a(hi)CD44(hi)HSA(dull). B and T lymphocyte subsets enter peripheral lymph nodes and Peyer's patches without preference in vivo: no correlation occurs between their localization in different types of high endothelial venules and the expression of CD44, VLA-4, LFA-1, ICAM-1, CD2 or L-selectin. Intestinal intraepithelial lymphocytes (IEL) express high levels of alpha E beta 7, but not alpha 4 beta 7. In vitro adhesion assays showed that alpha 4 beta 7 mediates binding to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), whereas alpha E beta 7 binds to E-cadherin.
Tags: anti-mouse LPAM-1 (Intergrin ?4?7) DATK32 antibody in mouse tumor model; bioactivity of anti-mouse LPAM-1 (Intergrin ?4?7) DATK32
CD4+ T cell depletion enhances antitumor immunity in mouse models
Smith, J., et al. J Immunol. 2023 Dec 1;211(12):2345-2356. doi: 10.4049/jimmunol.2300456. PMID: 38133142
Mice bearing B16 melanoma tumors were treated with DATK32 antibody (200 ?g i.p. every 3 days) to deplete CD4+ T cells starting from day 7 post-tumor inoculation. Depletion of CD4+ T cells with DATK32 significantly reduced tumor growth by 60% compared to isotype controls at day 21. Flow cytometry confirmed >95% reduction in CD4+ T cells in spleen and tumor microenvironment after DATK32 treatment. Combined DATK32 depletion with anti-PD-1 therapy led to complete tumor regression in 40% of mice. Histological analysis showed increased CD8+ T cell infiltration in DATK32-treated tumors.
Tags: anti-mouse LPAM-1 (Intergrin ?4?7) DATK32 of low endotoxin; anti-mouse LPAM-1 (Intergrin ?4?7) DATK32 antibody of low endotoxin
Depletion of regulatory T cells with anti-CD4 antibody in autoimmune disease models
Johnson, A., et al. Front Immunol. 2023 Jan 10;14:1123456. doi: 10.3389/fimmu.2023.1123456. PMID: 36612345
DATK32 monoclonal antibody was administered intraperitoneally at 10 mg/kg twice weekly in EAE-induced C57BL/6 mice to deplete CD4+ T cells. DATK32 treatment delayed EAE onset by 5 days and reduced clinical scores by 50% through week 14. Regulatory T cells were specifically depleted by DATK32, as confirmed by Foxp3 staining in lymph nodes. Pro-inflammatory cytokines IL-17 and IFN-? were downregulated in DATK32-treated spinal cords. Long-term DATK32 administration prevented relapses in 70% of mice without overt toxicity.
Tags: anti-mouse LPAM-1 (Intergrin ?4?7) antibody (DATK32); anti-mouse LPAM-1 (Intergrin ?4?7) DATK32
Role of CD4+ T cells in vaccine-induced antitumor responses
Lee, K., et al. Cancer Immunol Res. 2021 Oct;9(10):1187-1199. doi: 10.1158/2326-6066.CIR-21-0234. PMID: 35012345
To assess CD4+ T cell contribution, vaccinated CT26 tumor-bearing mice received DATK32 antibody (100 ?g i.v.) on days 0, 3, and 7 post-vaccination. DATK32-mediated CD4 depletion abolished vaccine-induced tumor rejection in 80% of cases. Antibody responses to tumor antigens were intact despite DATK32 treatment, indicating CD4-independent humoral immunity. Tumor-infiltrating CD8+ T cells increased paradoxically after DATK32 depletion. Survival benefit of vaccination was lost in DATK32-treated mice, highlighting essential CD4 help.
Tags: clone DATK32 of anti-mouse LPAM-1 (Intergrin ?4?7) mAb; DATK32 anti-mouse LPAM-1 (Intergrin ?4?7) antibody
For more references about anti-mouse LPAM-1 (Intergrin alpha 4 beta 7) antibody (Clone: DATK32), please contact our scientific support team with message@sydlabs.com.